StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CELZ yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $2.26 | $2.23 | -1.33% | 0.0M |
| 05-19 | $2.21 | $2.19 | -0.90% | 0.1M |
| 05-20 | $2.21 | $2.27 | +2.71% | 0.1M |
| 05-21 | $2.31 | $2.30 | -0.43% | 0.1M |
| 05-22 | $2.32 | $2.39 | +3.02% | 0.0M |
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $6.00K | $3.00K | $3.00K |
Operating Income | $-1.46M | $-6.14M | $-4.20M | $-2.92M |
Net Income | $-1.41M | $-6.00M | $-4.11M | $-2.87M |
EPS (Diluted) | $-0.38 | $-2.52 | $-1.72 | $-1.26 |
Total Assets | $6.44M | $7.81M | $5.85M | $7.11M |
Total Liabilities | $307.65K | $284.88K | $261.35K | $277.64K |
Cash & Equivalents | $5.72M | $7.21M | $5.38M | $6.54M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 3.70M | 3.70M | 2.58M | 2.58M |